Loading…
← CockpitCompetitor Analysis › 1302.HK LifeTech Scientific CorporationOpen in the cockpit ↗

LifeTech Scientific Corporation1302.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical Specialties
Momentum strong 64
Mkt cap
$771M
US dollars, full cap
Free float
83%
of shares outstanding
$/day
$7.13M
20-day average traded
Fwd P/E
19.8×
forward earnings
ROIC−WACC
-2.2 pp
WACC 8.6%
Hurdle
-6 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · HKDHK$1.45
1D0.0%
1W-4.3%
1M-1.4%
3M+8.2%
6M-30.3%
YTD-7.0%
1Y-24.1%
ATR %6.1%
52w lowhigh39.1% off high

What LifeTech Scientific does

Employees: 1,240

LifeTech Scientific at a glance

Size LifeTech Scientific (1302.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $771M, the 643rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$1.45 on 18 Nov 2026.

Performance Over six months the shares fell 30.3%, against -16.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue grew 0.8% over the last twelve months (peer median +12.6%); the operating margin is 12.3% (peer median 12.8%).

Valuation It trades at 19.8× forward earnings against a peer median of 20.0× (6th cheapest of 14).

Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -6 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.2 points below its cost of capital (8.6% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 851302.HK 68
Six months, rebased to 100: LifeTech Scientific against the median of its 20 peers (local-currency closes).

LifeTech Scientific financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.44BHK$1.49BHK$1.41BHK$1.40BHK$1.28B
Revenue growth—+5%+1%+10%—
Gross profitHK$1.10BHK$1.08BHK$1.05BHK$1.09BHK$1.00B
EBITDAHK$269MHK$260MHK$271MHK$390MHK$437M
Net incomeHK$62.4MHK$160MHK$241MHK$291MHK$378M
Free cash flowHK$544MHK$558MHK$176MHK$272MHK$231M
Capital expenditureHK$146MHK$148MHK$290MHK$306MHK$367M
Total debtn/aHK$8.95MHK$5.30MHK$10.2MHK$10.9M

Quarterly statements and history in the cockpit →

LifeTech Scientific competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%-10%0%+10%VREX2190CTKBMLABBBNXSETL300463688108002950300453603108301367688179096530AMSMCAP6888051302.HK6-month return →1-month return →
Up and to the right = strong over both horizons. LifeTech Scientific is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×VREX2190MLAB3004636881083004536031083013670965301302.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. LifeTech Scientific is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%2190MLAB300463688108300453603108INMD6881790965306888051302.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. LifeTech Scientific is the large dot.

LifeTech Scientific competitors and peer comparison

How LifeTech Scientific compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

LifeTech Scientific against its 20 peers (data as of 18 Nov 2026)
Measure1302.HKPeer medianRank in peer set
1-month return-1.4%-8.5%7th highest of 21
6-month return-30.3%-16.3%8th lowest of 21
Distance from 52-week high-39.1%-41.0%10th highest of 21
Revenue growth (TTM)+0.8%+12.6%4th lowest of 21
Operating margin12.3%12.8%10th lowest of 21
Forward P/E19.8×20.0×6th cheapest of 14
Growth the price implies (Req g, 7 yrs)9.6%7.9%7th most demanding of 14
Growth delivered (Del g)+15.5%+13.2%7th highest of 14
Hurdle (Req g minus delivered)-5.9 pp-1.4 pp7th least demanding of 14
ROIC minus cost of capital-2.2 pp-0.3 pp10th lowest of 21
EV / EBITDA17.0×13.1×3rd most expensive of 9
Net debt / EBITDA-5.3×0.2×2nd least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%19.8×9.6%+15.5%
Varex Imaging VREXUnited States$771M+79%+5%8%19.9×n/an/a
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%14.4×3.8%+105.8%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%n/an/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%11.5×21.3%+13.2%
Beta Bionics BBNXUnited States$779M+42%+44%-73%n/an/an/a
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%n/an/an/a
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%421.0×7.9%-10.2%
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%60.0×27.9%+9.9%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%n/an/an/a
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
Seegene 096530.KSSouth Korea$808M-26%+13%13%20.0×-6.7%-15.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%20.7×20.0%+21.4%
MedCap MCAP.STSweden$811M-4%+17%15%25.8×2.7%+20.9%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%n/an/an/a
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%n/a35.6%+17.1%

Questions

Which companies are LifeTech Scientific's closest peers?
The cockpit's peer set: Varex Imaging (VREX), Zylox-Tonbridge Medical Technology (2190.HK), Cytek Biosciences (CTKB), Mesa Laboratories (MLAB), Beta Bionics (BBNX), Standard Engineering Technology (SETL.NS), Maccura Biotechnology (300463.SZ), Sino Medical Sciences Technology (688108.SS).
Is LifeTech Scientific expensive compared with its peers?
On forward p/e it trades at 19.8× against a peer median of 20.0×, 6th cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -6 pp: the price already allows for a slowdown.
How has LifeTech Scientific stock performed?
Over six months to 18 Nov 2026 the shares returned -30.3% against -16.3% for the median peer; over one year -24.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.